Literature DB >> 17150286

The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.

Linda A Lininger1, Malford E Cullum, Mark B Lyles, Diane R Bienek.   

Abstract

Using a cross-sectional analysis design, we measured serum anti-protective antigen (PA) concentrations in individuals receiving six or fewer US licensed anthrax vaccinations. Samples were collected from 363 individuals with a mean of 29.6+/-8.42 months after their last vaccination (range 3-57 months). An enzyme-linked immunosorbent assay (ELISA) developed and validated by the Centers for Disease Control and Prevention (CDC) was used to evaluate the range and status of anthrax vaccine-induced serum antibody concentrations. A significant correlation (r=0.73, P< or =0.001) was found to exist between the number of vaccinations received and specific anti-PA immunoglobulin G (IgG) concentrations. We observed two discrete groups comprised of one to three doses (5.9-11.7 microg/ml) and four to six doses (26.2-30.2 microg/ml). These data indicate that anti-PA IgG is present at low but detectable levels after as few as two vaccinations (5.9+/-6.43 microg/ml). These findings may have significance for anthrax vaccine recipients who are unable to complete the primary or full regimen with this licensed product.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150286     DOI: 10.1016/j.vaccine.2006.11.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

2.  The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.

Authors:  William W Kwok; Junbao Yang; Eddie James; John Bui; Laurie Huston; Andrew R Wiesen; Michelle Roti
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

3.  Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccine.

Authors:  Diane R Bienek; Raymond E Biagini; David G Charlton; Jerome P Smith; Deborah L Sammons; Shirley A Robertson
Journal:  Clin Vaccine Immunol       Date:  2008-03-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.